Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was anticipating. In this photo illustration, a stack of pills is ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its most recent quarterly sales announcement: in spite of bottomless hype ...

Eli Lilly (LLY) CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a “financial impact” on the pharma giant. Ricks was ...

Nov 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

demand for weight loss drugs will stay robust. One estimate reckons the market for GLP-1 drugs could be worth as much as $150bn by 2031. The long-term outlook for Eli Lilly’s obesity business ...

Eli Lilly, a pharmaceutical company, filed three separate lawsuits against online vendors and a medical spa for making knock off weight loss drugs. The pharmaceutical company's popular weight loss ...

Patrik Jonsson, head of the division at Eli Lilly that is responsible for weight-loss drugs ... solution is to eliminate the needle entirely. Pills are not only simpler to make but also avoid ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third ...